TB-500 vs TB-500 Fragment 17-23

TB-500 and TB-500 Fragment 17-23 are research peptides derived from thymosin beta-4, a naturally occurring 43-amino-acid peptide involved in cytoskeletal regulation and tissue repair. TB-500 is a synthetic fragment that includes the full active region of Tβ4, while Fragment 17-23 is a minimal 7-amino-acid sequence that retains the actin-binding domain. Both peptides are investigated for injury recovery, but they differ in molecular size, mechanism, and the breadth of supporting evidence. This comparison highlights these differences to guide informed experimental design.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), comprising the active healing region (sequence: Ac-LKKTETQ, molecular weight ~889 g/mol). This region is responsible for promoting cell migration, angiogenesis, and tissue repair by sequestering G-actin and modulating cytoskeletal dynamics. Research suggests TB-500 accelerates wound healing, reduces inflammation, and supports cardiac repair in preclinical models. Notably, a handful of human randomized controlled trials (RCTs) have investigated its effects on wound healing and dry eye, and a dedicated safety trial in 40 healthy adults reported minimal adverse effects. Despite these studies, TB-500 remains unapproved for therapeutic use in major markets and is banned by WADA and in horse racing. Key research claims include accelerated wound healing, reduced inflammation, and promotion of cardiac repair.

TB-500 Fragment 17-23 (sequence: LKKTETQ) represents the minimal actin-binding domain of thymosin beta-4. This 7-amino-acid peptide retains the ability to sequester G-actin, a key step in promoting cell migration and wound healing. By focusing on this core functional motif, Fragment 17-23 offers a more concentrated approach to studying the actin-binding activity of Tβ4. However, its evidence base is limited compared to TB-500; no human clinical trials or dedicated safety studies have been published for this fragment. Preclinical research suggests it may replicate some healing effects of the full-length peptide, but the lack of direct comparative data means that its efficacy and safety profiles remain less characterized. Key research claims center on concentrated healing activity through actin sequestration.

Both TB-500 and TB-500 Fragment 17-23 are studied for injury recovery, including wound healing and tissue repair. TB-500 has additional research applications in anti-inflammatory models, where its broader peptide sequence may modulate immune responses beyond actin binding. In contrast, TB-500 Fragment 17-23 has no documented unique applications beyond those shared with TB-500. This overlap suggests that the minimal fragment may be useful for isolating the role of actin binding in recovery processes, while TB-500's additional domains could contribute to its broader anti-inflammatory effects. Researchers should consider these application differences when selecting a peptide for specific experimental endpoints.

TB-500: A safety-focused RCT in 40 healthy adults (2010) was designed specifically to assess the tolerability of synthetic thymosin beta-4 and found minimal adverse effects. Published human studies report no significant safety concerns, with common anecdotal side effects including injection site pain or redness, lightheadedness, mild headache, nausea, and fatigue. Animal studies also indicate a favorable safety profile at typical research doses. TB-500 Fragment 17-23: No specific safety data are available for this fragment. Given its truncated structure, researchers should exercise caution and assume potential risks similar to those of TB-500 until dedicated studies are conducted. The lack of human data underscores the need for rigorous preclinical safety assessment.